At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Alessandro Vannucchi, University of Florence, Florence, IT, discussed evidence-based treatment strategies across the disease spectrum of advanced systemic mastocytosis (AdvSM).
In this presentation, Vannucchi reviews the evolving therapeutic landscape in AdvSM, highlighting considerations that influence treatment selection across disease subtypes. Vannucchi discusses historical and contemporary treatment approaches, clinical evidence for KIT-targeted therapies, evolving goals for treatment, and emerging therapeutic strategies that may further inform future clinical management.
","author_name":"Scientific Education Support"}